BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
Molecular Imaging of the Hypoxic Tumor Microenvironment to Predict Response to Yttirum-90 Selective Internal Radiation Therapy in Hepatocellular Carcinoma- Pilot Study
Sponsor: Emory University
A EARLY_PHASE1 clinical study on BCLC Stage B Hepatocellular Carcinoma and BCLC Stage C Hepatocellular Carcinoma, this trial is completed. The trial is conducted by Emory University and has accumulated 8 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Completed EARLY_PHASE1
Status: Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2023 — Jun 2024 [monthly]
Recruiting EARLY_PHASE1
▶ Show 3 earlier versions
-
Jun 2022 — Jun 2023 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Jun 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emory University
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .